Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Thyroid Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neoplastic Syndromes, Hereditary 1Kidney Neoplasms 1Bone Neoplasms 1

Interventions

3-Iodobenzylguanidine 8lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 5Temozolomide 4Specimen Handling 4Magnetic Resonance Spectroscopy 4anlotinib 3Everolimus 3olaparib 2cabozantinib 2belzutifan 2Sunitinib 2Phenoxybenzamine 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1talazoparib 1spartalizumab 1pembrolizumab 1pazopanib 1lanreotide 1guadecitabine 1fluorodopa F 18 1fludarabine phosphate 1copper dotatate CU-64 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × Genetic Testing × Endocrine × Clear all
NCT03160274 2025-10-15

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

The University of Texas Health Science Center at San Antonio

Recruiting
2,000 enrolled
CNSEndocrineGenitourinaryHead & NeckSarcoma

Bone Neoplasms, Kidney Neoplasms, Neoplastic Syndromes, Hereditary, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡